Cancer treatments including chemotherapy and radiotherapy actively reshape the landscape of genetic mutations in healthy body tissues, driving a growth advantage for specific mutated cells. According to research published in Nature Genetics, combined chemoradiotherapy significantly increases normal cells carrying TP53 and PPM1D mutations within esophageal tissue.
As individuals age, healthy tissues naturally accumulate somatic mutations. While most of these genetic shifts go unnoticed, certain changes provide cells with a distinct growth advantage over their neighbors. When cancer develops, patients undergo intensive treatments like surgery, chemotherapy, radiotherapy, or combined chemoradiotherapy to eradicate the disease. New findings show that these medical interventions do not just impact malignant tumors; they actively alter the mutation landscape of surrounding healthy tissue.
DNA Sequencing Reveals How Chemoradiotherapy Selects Mutated Cells
Researchers utilized DNA sequencing to examine normal cells from the lining of the esophagus, known as the esophageal epithelium, collected from patients who underwent various treatment regimens prior to surgery. The investigation mapped out how different therapies impact these non-cancerous cells. Patients who received a combination of chemotherapy and radiotherapy exhibited a marked increase in normal cells carrying mutations in key genes.
The targeted genes include TP53, widely recognized as a critical tumor suppressor and often called the guardian of the genome. Researchers also observed an elevation in mutations affecting PPM1D, a gene responsible for producing an enzyme that manages both cell stress and TP53 function.
Chemotherapy Resistance and Healthy Tissue Protection
The genetic shifts in healthy tissue vary depending on the exact therapeutic approach. In patients treated with combination chemotherapy alone, sequencing revealed an increase in normal cells carrying mutations linked to resistance against the chemotherapy drug 5-fluorouracil, commonly referred to as 5-FU. This acquired resilience within healthy cells during treatment helps shield normal tissue from severe, life-threatening toxicities.
Despite the clear evidence that treatments reshape mutant cell fitness, the research team identified no specific mutational signatures associated with the chemotherapies themselves. Historically, cytotoxic drugs often leave behind tell-tale mutational signatures in normal genomes. The absence of these classic signatures in this context highlights a more complex dynamic where treatments select for pre-existing or stress-induced clonal populations rather than writing new mutational fingerprints directly onto the DNA.
Implications for Future Cancer Therapies and Side Effect Mitigation
Severe side effects in normal tissues frequently force clinicians to reduce doses of vital cancer treatments. Understanding how healthy cells respond to drugs opens new avenues for therapeutic design. The study suggests that identifying the protein domains and genes that render normal cells sensitive or resistant to specific drugs could help shape future cancer protocols to minimize collateral damage.
These insights may eventually inform the development of targeted treatments capable of destroying cancer cells while leaving healthy tissue completely unharmed. By cataloging the mutant cells selected during therapy, researchers hope to gain a deeper understanding of how tumors themselves eventually develop drug resistance. To validate these concepts on a broader scale, the research team has initiated a pilot study examining cheek swabs, blood, and urine samples from patients undergoing treatment for skin, head, and neck cancers.
Ещё по этой теме
